These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
358 related articles for article (PubMed ID: 28124511)
21. Ledipasvir/sofosbuvir fixed-dose combination for treatment of hepatitis C virus genotype 4 infection. Nehra V; Tan EM; Rizza SA; Temesgen Z Drugs Today (Barc); 2016 Feb; 52(2):111-7. PubMed ID: 27092340 [TBL] [Abstract][Full Text] [Related]
22. Efficacy and Safety of Ribavirin with Sofosbuvir Plus Ledipasvir in Patients with Genotype 1 Hepatitis C: A Meta-Analysis. He QF; Zhang QF; Zhang DZ Dig Dis Sci; 2016 Nov; 61(11):3108-3117. PubMed ID: 27619394 [TBL] [Abstract][Full Text] [Related]
23. Ledipasvir/Sofosbuvir versus Daclatasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Genotype 4 Patients. Abdelaty LN; Elnaggar AA; Said AA; Hussein RRS Curr Drug Saf; 2020; 15(1):53-60. PubMed ID: 31573893 [TBL] [Abstract][Full Text] [Related]
24. Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study. Osinusi A; Kohli A; Marti MM; Nelson A; Zhang X; Meissner EG; Silk R; Townsend K; Pang PS; Subramanian GM; McHutchison JG; Fauci AS; Masur H; Kottilil S Ann Intern Med; 2014 Nov; 161(9):634-8. PubMed ID: 25364884 [TBL] [Abstract][Full Text] [Related]
25. Ledipasvir-sofosbuvir: interferon-/ribavirin-free regimen for chronic hepatitis C virus infection. Smith MA; Chan J; Mohammad RA Ann Pharmacother; 2015 Mar; 49(3):343-50. PubMed ID: 25515863 [TBL] [Abstract][Full Text] [Related]
26. The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection. Balistreri WF; Murray KF; Rosenthal P; Bansal S; Lin CH; Kersey K; Massetto B; Zhu Y; Kanwar B; German P; Svarovskaia E; Brainard DM; Wen J; Gonzalez-Peralta RP; Jonas MM; Schwarz K Hepatology; 2017 Aug; 66(2):371-378. PubMed ID: 27997679 [TBL] [Abstract][Full Text] [Related]
27. Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection. Abergel A; Metivier S; Samuel D; Jiang D; Kersey K; Pang PS; Svarovskaia E; Knox SJ; Loustaud-Ratti V; Asselah T Hepatology; 2016 Oct; 64(4):1049-56. PubMed ID: 27351341 [TBL] [Abstract][Full Text] [Related]
28. Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation: a Japanese multicenter experience. Ueda Y; Ikegami T; Akamatsu N; Soyama A; Shinoda M; Goto R; Okajima H; Yoshizumi T; Taketomi A; Kitagawa Y; Eguchi S; Kokudo N; Uemoto S; Maehara Y J Gastroenterol; 2017 Aug; 52(8):986-991. PubMed ID: 28138756 [TBL] [Abstract][Full Text] [Related]
29. Treatment of hepatitis C virus recurrence after transplantation with sofosbuvir/ledipasvir: The role of ribavirin. Globke B; Raschzok N; Teegen EM; Pratschke J; Schott E; Eurich D Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27943544 [TBL] [Abstract][Full Text] [Related]
30. Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCV NS3/4A Inhibitors. Kanda T; Yasui S; Nakamura M; Suzuki E; Arai M; Ooka Y; Ogasawara S; Chiba T; Saito T; Haga Y; Takahashi K; Sasaki R; Wu S; Nakamoto S; Tawada A; Maruyama H; Imazeki F; Kato N; Yokosuka O Int J Mol Sci; 2017 Apr; 18(5):. PubMed ID: 28441362 [TBL] [Abstract][Full Text] [Related]
31. Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens. Wyles D; Pockros P; Morelli G; Younes Z; Svarovskaia E; Yang JC; Pang PS; Zhu Y; McHutchison JG; Flamm S; Lawitz E Hepatology; 2015 Jun; 61(6):1793-7. PubMed ID: 25846014 [TBL] [Abstract][Full Text] [Related]
32. A different perspective on sofosbuvir-ledipasvir treatment of patients with HCV genotype 1b cirrhosis: The ital-c network study. Barone M; Iannone A; Shahini E; Ippolito AM; Brancaccio G; Morisco F; Milella M; Messina V; Smedile A; Conti F; Gatti P; Santantonio T; Tundo P; Lauletta G; Napoli N; Masetti C; Termite AP; Francavilla R; Di Leo A; Pesce F; Andriulli A J Viral Hepat; 2018 Jan; 25(1):56-62. PubMed ID: 28787102 [TBL] [Abstract][Full Text] [Related]
33. Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naïve, genotype 1 hepatitis C infected patients. Curry MP; Tapper EB; Bacon B; Dieterich D; Flamm SL; Guest L; Kowdley KV; Lee Y; Milligan S; Tsai N; Younossi Z; Afdhal NH Aliment Pharmacol Ther; 2017 Sep; 46(5):540-548. PubMed ID: 28691377 [TBL] [Abstract][Full Text] [Related]
34. Safety and Efficacy of Ledipasvir-Sofosbuvir With or Without Ribavirin for Chronic Hepatitis C in Children Ages 6-11. Murray KF; Balistreri WF; Bansal S; Whitworth S; Evans HM; Gonzalez-Peralta RP; Wen J; Massetto B; Kersey K; Shao J; Garrison KL; Parhy B; Brainard DM; Arnon R; Gillis LA; Jonas MM; Lin CH; Narkewicz MR; Schwarz K; Rosenthal P Hepatology; 2018 Dec; 68(6):2158-2166. PubMed ID: 30070726 [TBL] [Abstract][Full Text] [Related]
35. Ledipasvir/sofosbuvir-based treatment of patients with chronic genotype-1 HCV infection and cirrhosis: results from two Phase II studies. Lawitz E; Poordad F; Hyland RH; Wang J; Liu L; Dvory-Sobol H; Brainard DM; McHutchison JG; Gutierrez JA Antivir Ther; 2016; 21(8):679-687. PubMed ID: 27348483 [TBL] [Abstract][Full Text] [Related]
36. A phase IIIb study of ledipasvir/sofosbuvir fixed-dose combination tablet in treatment-naïve and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus. Lim YS; Ahn SH; Lee KS; Paik SW; Lee YJ; Jeong SH; Kim JH; Yoon SK; Yim HJ; Tak WY; Han SY; Yang JC; Mo H; Garrison KL; Gao B; Knox SJ; Pang PS; Kim YJ; Byun KS; Kim YS; Heo J; Han KH Hepatol Int; 2016 Nov; 10(6):947-955. PubMed ID: 27198664 [TBL] [Abstract][Full Text] [Related]
37. Sofosbuvir plus ledipasvir in combination for the treatment of hepatitis C infection. Bourlière M; Adhoute X; Ansaldi C; Oules V; Benali S; Portal I; Castellani P; Halfon P Expert Rev Gastroenterol Hepatol; 2015; 9(12):1483-94. PubMed ID: 26595560 [TBL] [Abstract][Full Text] [Related]
38. Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older. Saab S; Park SH; Mizokami M; Omata M; Mangia A; Eggleton E; Zhu Y; Knox SJ; Pang P; Subramanian M; Kowdley K; Afdhal NH Hepatology; 2016 Apr; 63(4):1112-9. PubMed ID: 26704693 [TBL] [Abstract][Full Text] [Related]
39. Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials. Alqahtani SA; Afdhal N; Zeuzem S; Gordon SC; Mangia A; Kwo P; Fried M; Yang JC; Ding X; Pang PS; McHutchison JG; Pound D; Reddy KR; Marcellin P; Kowdley KV; Sulkowski M Hepatology; 2015 Jul; 62(1):25-30. PubMed ID: 25963890 [TBL] [Abstract][Full Text] [Related]
40. Ledipasvir/sofosbuvir without ribavirin is effective in the treatment of recurrent hepatitis C virus infection post-liver transplant. Shoreibah M; Orr J; Jones D; Zhang J; Venkata K; Massoud O Hepatol Int; 2017 Sep; 11(5):434-439. PubMed ID: 28083718 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]